H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on VYGR stock, giving a Buy rating today. Patrick ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on November 1. Phil Nadeau’s rating ...

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $9 million in its third quarter. On a per-share basis, the Lexington, Massachusetts-based ...

Analysts expect Voyager Therapeutics to report an earnings per share (EPS) of $-0.49. Investors in Voyager Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...